Depression

Anti-Depressants Raise Relapse Risk

Patients who use anti-depressants are much more likely to suffer relapses of major depression than those who use no medication at all, concludes a McMaster researcher.

In a paper that is likely to ignite new controversy in the hotly debated field of depression and medication, evolutionary psychologist Paul Andrews concludes that patients who have used anti-depressant medications can be nearly twice as susceptible to future episodes of major depression.

Andrews, an assistant professor in the Department of Psychology, Neuroscience & Behaviour, is the lead author of a new paper in the Journal Frontiers of Psychology.

The meta-analysis suggests that people who have not been taking any medication are at a 25 per cent risk of relapse, compared to 42 per cent or higher for those who have taken and gone off an anti-depressant.

Andrews and his colleagues studied dozens of previously published studies to compare outcomes for patients who used anti-depressants compared to those who used placebos.
They analyzed research on subjects who started on medications and were switched to placebos, subjects who were administered placebos throughout their treatment, and subjects who continued to take medication throughout their course of treatment.

Andrews says anti-depressants interfere with the brain’s natural self-regulation of serotonin and other neurotransmitters, and that the brain can overcorrect once medication is suspended, triggering new depression.

Though there are several forms of anti-depressants, all of them disturb the brain’s natural regulatory mechanisms, which he compares to putting a weight on a spring. The brain, like the spring, pushes back against the weight. Going off antidepressant drugs is like removing the weight from the spring, leaving the person at increased risk of depression when the brain, like the compressed spring, shoots out before retracting to its resting state.

“We found that the more these drugs affect serotonin and other neurotransmitters in your brain — and that’s what they’re supposed to do — the greater your risk of relapse once you stop taking them,” Andrews says. “All these drugs do reduce symptoms, probably to some degree, in the short-term. The trick is what happens in the long term. Our results suggest that when you try to go off the drugs, depression will bounce back. This can leave people stuck in a cycle where they need to keep taking anti-depressants to prevent a return of symptoms.”

Andrews believes depression may actually be a natural and beneficial — though painful
— state in which the brain is working to cope with stress. [continue reading…]

depressed womanIn a recent issue of Psychotherapy and Psychosomatics a group of German investigators headed by Eva Brakemeier has performed a pilot study to test a new approach for chronic depression.

This study demonstrates that the inpatient cognitive behavioral analysis system of psychotherapy (CBASP) program can be considered as a promising and feasible treatment option that produces a good outcome for chronically depressed patients with high comorbidity in the short and long term. Future randomized controlled studies should examine whether this intensive CBASP program is more effective than standard psychiatric interventions or CBASP outpatient treatment.

Cognitive behavioral analysis system of psychotherapy (CBASP) was initially developed as an outpatient treatment for chronic depression. It integrates cognitive-emotional, behavioral, interpersonal, and psychodynamic theories and strategies by addressing directly the specific psychopathology of chronic depression. Given the high degree of suicidality, comorbidity, and therapy resistance in chronic depression, however, many of these patients require inpatient treatment.

In this study, the investigators report on a first specialized program for chronic depression adapting CBASP to an inpatient setting and evaluate the feasibility and short- as well as long-term outcome of it. The new CBASP group therapy focuses on a modified approach for conducting situation analysis and on Kiesler’s circle training with the extensive use of role playing and shaping. The entire treatment team was trained in CBASP; regular workshops and weekly supervisions for both the team and the individual therapists were conducted. Specific CBASP elements were implemented in other accompanying treatments such as nurse encounters, physiotherapy, music therapy, and occupational group therapy. A patient support group was established to avoid relapse after discharge. Patients received optimized pharmacotherapy in addition to the CBASP program in compliance with current national and international guidelines for depression treatment. [continue reading…]

Fog, clouds or smog

Creative Commons ~Halvekip

Long-term exposure to air pollution can lead to physical changes in the brain, as well as learning and memory problems and even depression, new research in mice suggests.

While other studies have shown the damaging effects of polluted air on the heart and lungs, this is one of the first long-term studies to show the negative impact on the brain, said Laura Fonken, lead author of the study and a doctoral student in neuroscience at Ohio State University.

“The results suggest prolonged exposure to polluted air can have visible, negative effects on the brain, which can lead to a variety of health problems,” Fonken said.

“This could have important and troubling implications for people who live and work in polluted urban areas around the world.”

The study appears online this week in the journal Molecular Psychiatry.

For this study, Fonken and colleagues in Ohio State’s Department of Neuroscience collaborated with researchers in the university’s Davis Heart and Lung Research Institute.

In previous studies in mice, the Davis research group – including Qinghua Sun, associate professor of environmental health sciences, and Sanjay Rajagopalan, professor of cardiovascular medicine — found that fine air particulate matter causes widespread inflammation in the body, and can be linked to high blood pressure, diabetes and obesity. This new study aimed to extend their research on air pollution to the brain. [continue reading…]

Research reveals the truth behind the use of antidepressants by women in England and Wales: a huge number of women use antidepressants for long periods without being reviewed or offered any alternatives to drugs.antidepressantsbriefing download PDF
The research, conducted by Opinium LLP*, shows that a huge number of women use antidepressants for long periods without being reviewed or offered any alternatives to drugs. It shows:

  • a third of women have taken antidepressants at some point in their lives
  • nearly half (48%) of women currently on antidepressants have been on them for five years or more
  • one in four (24%) women currently on antidepressants have been on them for 10 years or more
  • one in four (24%) women currently on antidepressants have waited a year or more for a review.

National Institute for Clinical Excellence (NICE) guidelines advise that antidepressants should not be used routinely as the only option offered to people for depression. For moderate or severe depression a combination of medication and high-intensity psychological intervention is recommended. Therefore the number of women who have taken antidepressants and the number who were not offered alternative or additional support poses worrying questions about the appropriateness of prescriptions. The lack of choices means:

The lack of choice means 57% of women who have taken antidepressants weren’t offered any alternatives to drugs at time of prescription.

Not only that, many women are hiding the problem. Nearly one in five (18%) women kept it a secret from their family and 10% even kept it a secret from their partner. Download the briefing Checks and choices: women and antidepressants

Source:Platform 51